Investigational drug · Phase 3
pMDI HFA-152a
Also called: CHF5993 100, CHF5993 200, HFA-152a propellant, pMDI HFA-134a, HFA-134a propellant
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "pMDI HFA-152a"
First trial start
2023
Nov 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "pMDI HFA-152a", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "pMDI HFA-152a" as an intervention, largest first.
- Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).Pivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT06264674 · 827 participants · Start Nov 27, 2023 · Primary completion Feb 18, 2025
Drug: CHF5993 200/6/12.5 μg pMDI HFA-152a; Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a · For: Asthma
Sites: Burgas, Bulgaria; Kozloduy, Bulgaria; Momchilgrad, Bulgaria · 118 sites in all
- Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate AsthmaPivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07301736 · 780 participants (planned) · Start Dec 17, 2025 · Primary completion Jun 3, 2027
Drug: CHF5993 pMDI with HFA-152a; CHF5993 pMDI with HFA-134a and 1 more · For: Asthma
Sites: Buenos Aires, Argentina; Ciudad Autonoma de Buenos Aire, Argentina; Córdoba, Argentina · 167 sites in all
- Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With AsthmaPivotal-lookingNot yet recruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07858123 · 700 participants (planned) · Start Nov 16, 2026 · Primary completion Jun 26, 2030
Drug: CHF5993 100/6/12.5 μg pMDI HFA-152a; Seretide Evohaler · For: Asthma
Sites: Frankfurt, Germany; Göttingen, Germany; Jena, Germany · 25 sites in all
- Efficacy and Safety of CHF 5993 100/6/12.5 μg HFA-152a pMDI in Patients With Asthma Uncontrolled on Medium Doses of Inhaled Corticosteroids in Combination With Long-acting ß2-agonistsPivotal-lookingRecruiting
Chiesi Farmaceutici S.p.A.Industry
NCT07546981 · 554 participants (planned) · Start Jun 26, 2026 · Primary completion Oct 17, 2028
Drug: Experimental: Participant Group CHF 5993 pMDI HFA-152a · For: Asthma
Sites: Beijing, China · 2 sites in all
Chiesi Farmaceutici S.p.A.Industry
NCT05472662 · 25 participants · Start Aug 3, 2022 · Primary completion Oct 31, 2022
Drug: Placebo 152a; Placebo 134a · For: Asthma
Sites: Manchester, United Kingdom
GlaxoSmithKlineGSK (GSK)
NCT06702462 · 20 participants · Start Mar 11, 2025 · Primary completion Jun 4, 2025
Drug: HFA-152A propellant; HFA-134A propellant · For: Asthma
Sites: Marlton, New Jersey; Huntersville, North Carolina; San Antonio, Texas
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.